© 2019 Medicare Genetic Solutions

332nd Federal Way, WA 98023

Tel: 253-831-6056

Clinical Study for Genetic Cancer Screening and Pharmacogenomics

Genetic Cancer Screening (CGX): The intent of the study is to determine the incidence of abnormal genetic proclivities in individuals who have a personal or family history of cancer. Once a specific genetic proclivity is determined the patient could start a nutritional supplementation program specific to this cancer genetic marker.


An example of this would be, a patient has a positive result for the Colon Cancer marker, it is well determined a Vit D deficiency is a high-risk factor for Colon Cancer. The patient would be advised to do a blood test for Vit D. Once the result is obtained a course of Vit D supplementation would commence.


The intent is to follow these patients to determine if proactive nutritional intervention alters favorably the onset of the cancer associated with the positive marker. Further, we intend to calculate the relational incidence of patients who have a family history of cancer and their specific cancer marker profile. It is our hypothesis, early determination and early proactive nutritional intervention will change the trajectory of cancer occurrence in those patients with a family history and them having the specific cancer marker.

Pharmacogenomics Screening (PGX): The intent of the study is to determine for those patients who are under treatment or about to go into treatment with one or several drugs including over-the-counter drugs with any of the sequences of biochemical reactions, catalyzed by enzymes, known to be influenced by genetic variation in a patient population, as well as, any patient currently or contemplating taking up to 5 different medications. The PGX Test will assess the association of genes with patient’s diseases, patient’s target medications or with substitute medications considered as replacements for target drugs.

We intend to determine for those patients who are taking suboptimum medication based on their genetic predisposition towards those medications what the potential savings could be to the underlying healthcare system. We will determine repeat MD office visits for unresolved issues potentially do due to suboptimal treatment modalities, determine unneeded ER visits based on suboptimal medication treatment as well as a subjective quality of life evaluation pre and post testing.

The overall intent is to work with the treating MD to explain the results and to suggest alternative medications which are more in line with the patients pharmacogenetic profile.